PhenoPath
Diagnoses you can count on®

PCR

PhenoPath Laboratories strives to be the world's Gold Standard pathology reference laboratory. We are committed to rigorous testing, definitive diagnosis, and outstanding customer service, with an emphasis on accuracy, integrity, innovation, and accessibility to clients.

PhenoPath offers a menu of PCR assays to aid in the diagnosis of hematopoietic neoplasms and to provide information regarding prognosis and potential therapeutic targets for solid tumors. For information regarding specific tests, please visit our website, email us at lab@phenopath.com, or contact Client Services or your Regional Sales Manager (888-927-4366).

General Features / Benefits of PhenoPath PCR assays

- Reviewed & signed out by experienced board-certified pathologists
- Pathologists & technologists available to address your clinical & technical questions
- Rigorous test validation and quality control
- Rapid turn around time

Hematopathology Testing

- IGH and IGK chain gene rearrangement PCR assays to evaluate for clonal B cell/plasma cell populations in the workup of B-lymphoid neoplasms
- T cell receptor gamma (TCR-gamma) and T cell receptor beta (TCR-beta) gene rearrangement PCR assays to evaluate for clonal T cell populations in the workup of T cell neoplasms
- Gene rearrangement assays based on landmark European Biomed-2 consortium recommendations
- Assays utilize capillary electrophoresis and/or real time/quantitative PCR technologies
- BCR-ABL, JAK2 V617F and Calreticulin testing to aid in the diagnostic work-up of myeloproliferative neoplasms
- BRAF V600 mutation testing to aid in the diagnosis of hairy cell leukemia and Langerhans cell neoplasms; MYD88 L265P mutation testing to aid in the diagnosis of lymphoplasmacytic lymphoma

Solid Tumor Testing

- FDA approved assay to detect clinically relevant EGFR mutations in formalin fixed paraffin embedded non-small cell carcinoma tissue samples
- FDA approved assay to detect clinically relevant EGFR mutations in plasma samples from non-small cell carcinoma patients
- FDA approved assay to detect KRAS codon 12 and 13 mutations in colorectal carcinomas
- FDA approved assay to detect BRAF V600 mutations in melanoma
- PCR based assay for the detection of microsatellite instability (MSI) using mono-allelic repeats
- BRAF V600 mutation testing for colorectal carcinomas, gliomas, thyroid neoplasms, etc.

PhenoPath
Diagnoses you can count on®

HEMATOPATHOLOGY			
	TEST	**DESCRIPTION**	**TEST #**
PCR	IGH Chain Gene Rearrangement Studies	Detects rearrangements of the immunoglobulin heavy chain locus to assess for clonality.	PCR0001
PCR	IGK (Kappa) Gene Rearrangement Studies	Detects rearrangements of the immunoglobulin kappa chain locus to assess for clonality.	PCR0009
PCR	TCR-γ (Gamma) Chain Gene Rearrangement Studies	Detects rearrangements of the T cell receptor gamma locus to assess for clonality.	PCR0002
PCR	TCR-ß (Beta) Chain Gene Rearrangement Studies	Detects rearrangements of the T cell receptor beta locus to assess for clonality.	PCR0022
PCR	Quantitative BCR-ABL1 Major Breakpoint Cluster (Mbcr) by Real Time PCR	Quantitative assay for the BCR-ABL1 major breakpoint cluster region (Mbcr/p210) transcript using international scale (IS) reporting.	PCR0013
PCR	Quantitative BCR-ABL1 Minor Breakpoint Cluster (mbcr) by Real Time PCR	Quantitative assay for the BCR-ABL1 minor breakpoint cluster region (mbcr/p190) transcript.	PCR0014
PCR	JAK2 by Real Time PCR	Qualitative assay detects the JAK2 V617F mutation, to aid in the diagnosis of myeloproliferative neoplasms.	PCR0010
PCR	Calreticulin (CALR) PCR	Detects insertion/deletion mutations in exon 9 of the Calreticulin gene, to aid in the diagnosis of myeloproliferative neoplasms.	PCR0024
PCR	MYD88 L265P Mutation	Qualitative PCR assay detects the MYD88 L265P mutation	PCR0023

SOLID TUMOR			
	TEST	**DESCRIPTION**	**TEST #**
PCR; IVD	EGFR cobas IVD	FDA-approved Roche cobas EGFR Mutation Test detects clinically relevant EGFR mutations to identify NSCLC patients eligible for treatment with Tarceva; and to identify the T790M mutation, indicating eligibility for treatment with Tagrisso.	PCR0025
PCR; IVD	Cobas EGFR plasma	FDA-approved Roche cobas EGFR Mutation Test detects EGFR mutations in plasma samples from NSCLC patients for monitoring/therapeutic decision-making purposes.	PCR0028
PCR; IVD	KRAS therascreen IVD	FDA-approved QIAGEN therascreen KRAS RGQ PCR test used to detect the major KRAS mutations involving codons 12 and 13.	PCR0016
PCR; IVD	BRAF IVD cobas V600	FDA-approved Roche cobas BRAF Mutation Test used to detect the V600 BRAF activating mutation in cases of melanoma to predict of patient responsiveness to anti-BRAF directed therapy.	PCR0015
PCR	BRAF V600	Qualitative PCR assay detects the V600 BRAF activating mutation in colorectal carcinomas.	PCR0011
PCR	MSI PCR	PCR assay to detect microsatellite instability, which is the end result of a defective mismatch repair (MMR) system.	PCR0017